These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 32107748

  • 1. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years.
    Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B.
    Neurol Ther; 2020 Jun; 9(1):105-115. PubMed ID: 32107748
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, Gundapaneni B, Schwartz JH.
    Amyloid; 2019 Dec; 26(4):203-209. PubMed ID: 31353964
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
    Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A.
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug 17; 8(5):529-538. PubMed ID: 33895806
    [Abstract] [Full Text] [Related]

  • 9. Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
    Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ.
    Future Cardiol; 2023 Jan 17; 19(1):7-17. PubMed ID: 36715498
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Mundayat R, Stewart M, Alvir J, Short S, Ong ML, Keohane D, Rill D, Sultan MB.
    Neurol Ther; 2018 Jun 17; 7(1):87-101. PubMed ID: 29633228
    [Abstract] [Full Text] [Related]

  • 14. A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.
    Waddington Cruz M, Benson MD.
    Neurol Ther; 2015 Dec 17; 4(2):61-79. PubMed ID: 26662359
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
    Coelho T, Inês M, Conceição I, Soares M, de Carvalho M, Costa J.
    Neurology; 2018 Nov 20; 91(21):e1999-e2009. PubMed ID: 30333157
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.
    J Neurol; 2016 May 20; 263(5):916-924. PubMed ID: 26984605
    [Abstract] [Full Text] [Related]

  • 19. Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.
    Li B, Alvir J, Stewart M.
    Cardiol Ther; 2020 Dec 20; 9(2):535-540. PubMed ID: 32524297
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.